Nuclear VCP drives colorectal cancer progression by promoting fatty acid oxidation
Youwei Huang, Fang Wang, Xi Lin, Qing Li, Yuli Lu, Jiayu Zhang, Xi Shen, Jingyi Tan, Zixi Qin, Jiahong Chen, Xueqin Chen, Guopeng Pan, Xiangyu Wang, Yuequan Zeng, Shangqi Yang, Jun Liu, Fan Xing, Kai Li, Haipeng Zhang
Abstract
Fatty acid oxidation (FAO) fuels many cancers. However, knowledge of pathways that drive FAO in cancer remains unclear. Here, we revealed that valosin-containing protein (VCP) upregulates FAO to promote colorectal cancer growth. Mechanistically, nuclear VCP binds to histone deacetylase 1 (HDAC1) and facilitates its degradation, thus promoting the transcription of FAO genes, including the rate-limiting enzyme carnitine palmitoyltransferase 1A ( CPT1A ). FAO is an alternative fuel for cancer cells in environments exhibiting limited glucose availability. We observed that a VCP inhibitor blocked the upregulation of FAO activity and CPT1A expression triggered by metformin in colorectal cancer (CRC) cells. Combined VCP inhibitor and metformin prove more effective than either agent alone in culture and in vivo. Our study illustrates the molecular mechanism underlying the regulation of FAO by nuclear VCP and demonstrates the potential therapeutic utility of VCP inhibitor and metformin combination treatment for colorectal cancer.